Open Access<p>Lentinan Inhibits AGE-Induced Inflammation and the Expression of Matrix-Degrading Enzymes in Human Chondrocytes</p>
Author(s) -
Zhaozhen Zhang,
Zhuqing Zha,
Zhiwei Zhao,
Wenjing Liu,
Wuyin Li
Publication year - 2020
Publication title -
drug design, development and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.964
H-Index - 64
ISSN - 1177-8881
DOI - 10.2147/dddt.s243311
Subject(s) - lentinan , inflammation , mmp3 , matrix metalloproteinase , chemistry , tumor necrosis factor alpha , thrombospondin 1 , adamts , chondrocyte , nitric oxide , western blot , pharmacology , cancer research , thrombospondin , immunology , microbiology and biotechnology , medicine , biochemistry , metalloproteinase , gene expression , biology , polysaccharide , angiogenesis , organic chemistry , in vitro , gene
Chondrocyte-mediated inflammation is an important pathological component of osteoarthritis (OA) development. There are currently no therapies that completely reverse the development of OA. Lentinan, a type of polysaccharide derived from Lentinus edodes, has been demonstrated to possess significant anti-viral, anti-cancer, and anti-inflammatory effects, and has been recently used in the treatment of several inflammatory diseases. However, little research has focused on the pharmacological effect of lentinan in human OA.